Report contents
Industry landscape
Where the company competes: three marketed drugs in ATTR-CM
Alnylam Pharmaceuticals is an RNA interference company. RNAi is a natural cellular process that silences genes; Alnylam engineers small interfering RNA (siRNA) to shut down production of a disease-causing protein at its genetic source, which differs from drugs that block a protein after it forms. The rest of the chain is conventional. Oligonucleotide chemistry and the galNAc sugar conjugate that delivers siRNA into liver cells sit upstream; contract manufacturing and fill-finish sit in the middle; specialty pharmacies, prescribing cardiologists and neurologists, and payers sit at the commercial end. In the United States, Medicare and the 340B drug discount program, which lets qualifying hospitals buy outpatient drugs at a discount, sit between the prescription and the revenue line.
Almost all of Alnylam's economics now rest on one disease. Transthyretin (TTR) amyloidosis is caused by misfolded TTR protein depositing in nerves and heart muscle. The class splits into ATTR-PN, the polyneuropathy form, and ATTR-CM, the cardiomyopathy form, which is far larger and where the growth now comes from. Alnylam's TTR franchise, Amvuttra (vutrisiran) and Onpattro (patisiran), generated $1.15 billion in the third quarter of 2026, up 59% from a year earlier, the company reported. Management guides to $4.2 billion to $4.5 billion of TTR revenue for the full year inside $4.7 billion to $5.1 billion of total net product revenue, and the CFO said the full-year figure will likely land at the low end. The gap between those ranges leaves about $0.2 billion to $0.9 billion for everything else Alnylam sells, so TTR is roughly 82% to 96% of guided product revenue. Defining the market precisely is most of the work of valuing the company.
Geography matters less than the product labels suggest. Amvuttra is sold in the US, Europe and Japan, but the arena is national because reimbursement is national, and the near-term swing factor is American: the 340B pricing update scheduled for January 1, 2027. Management said on the October 2026 earnings call that health-system ordering could turn volatile in the fourth quarter as providers reassess site-of-care economics. Truist Securities estimates 15-20% of Amvuttra volume is directly exposed, an outside estimate rather than a company figure; Alnylam has not sized the exposure itself.
The competitive set is small enough to table.
| Company | Product | Mechanism | Labeled ATTR use |
|---|---|---|---|
| Pfizer | tafamidis (Vyndaqel/Vyndamax) | TTR stabilizer | ATTR-CM |
| BridgeBio Pharma | acoramidis (Attruby) | TTR stabilizer | ATTR-CM |
| Alnylam | vutrisiran (Amvuttra) | RNAi silencer | ATTR-PN; ATTR-CM since March 2025 |
| Alnylam | patisiran (Onpattro) | RNAi silencer | ATTR-PN |
| Ionis / AstraZeneca | eplontersen (Wainua) | antisense silencer | ATTR-PN |
Three drugs are approved for ATTR-CM: tafamidis, on the market since 2019, acoramidis, launched in late 2024, and Amvuttra, cleared for the heart indication in March 2025. Amvuttra is the only one of the five products approved in both forms of the disease, which gives Alnylam a bridge between the neurology and cardiology prescribing audiences. At least one one-time gene-editing candidate is in late-stage testing for ATTR-CM; if it succeeds, a fourth mechanism joins the class.
Barriers to entry: high. Concentration: moderate. No one reaches the ATTR-CM market without a large outcomes trial, years of follow-up and payer negotiations, which is why the approved list is short. The restraint is that a high approval hurdle has not produced pricing power. Once three therapies are reimbursed, competition moves to clinical profile, physician familiarity and contracting, and Alnylam is the newest entrant in the heart indication. Franchise revenue rose 59% year over year, which by itself says nothing about share; the case that Alnylam is losing ground rests on rival growth and on the guidance cut earlier in 2026, and no measured share series backs it. Pfizer, BridgeBio and Alnylam all report product revenue rather than units, so any share figure for the class is an estimate.
The practical question for concentration is whether the leaders can be counted on one hand. In ATTR-CM they can, barely, and the count is rising; in ATTR-PN three products already compete. Barriers to getting in look high while barriers to earning excess returns look considerably lower. The binding constraint on the market itself is diagnosis and physician habit: Alnylam says two-thirds of potential prescribers have yet to write a script for Amvuttra, so the near-term ceiling has as much to do with adoption as with rivals. What would settle the competitive question is whether Amvuttra's share of new ATTR-CM starts stabilizes as those prescribers begin to use it. The company's 2027 guidance, now due in February rather than the usual January, is the next place that shows up.
Competitive advantage
Does the company have a moat? Moderate, and only recently earned
Overall moat rating: Moderate. A moat shows up in two places: industry structure that keeps entrants out, and returns that stay above the cost of capital once entrants are kept out. Alnylam clears the first test and has only begun to clear the second. ATTR amyloidosis is hard to enter — three drugs carry a cardiomyopathy label after years of cardiovascular outcomes work — yet Alnylam's operating line was negative in each of fiscal 2021 through 2024, and its first profitable year was fiscal 2025, when it reported $0.31 billion of net income on $3.71 billion of revenue. High barriers that have not yet produced above-normal returns describe a young franchise, not a proven moat. Today the evidence supports Moderate, not Fairly Strong.
Market position: two of five TTR drugs, the only label in both forms
Market position: Fairly Strong. Alnylam sells two of the five approved products that lower or silence transthyretin, and Amvuttra is the only one labeled for both the neuropathy and cardiomyopathy forms of the disease. That dual label lets the company reach neurologists and cardiologists with one molecule and gives it a bridge between the two audiences as patients progress from nerve to heart involvement. In ATTR-PN it is the incumbent. In ATTR-CM, which is the larger market and where the growth sits, it is the newest of three approvals, behind Pfizer's tafamidis (2019) and BridgeBio's acoramidis (launched late 2024).
Share is where the rating gets soft. All three sellers report product revenue, not units or prescriptions, and no measured share series for the class is publicly available, so any share figure would be a reconstruction. The company's TTR franchise revenue of $1.15 billion in the third quarter of 2026, up 59% year over year, proves the franchise is growing fast. It does not prove Alnylam is gaining on either rival, since both are plausibly growing too and their growth rates are not in evidence.
Stability: Moderate. Greenwald's share-stability benchmark is the right instinct but the wrong lens here. The framework treats a five-year average share change under 2 percentage points as evidence of strong barriers, and a change above 5 points as evidence barriers are absent. Alnylam's share of ATTR-CM went from zero to a real position because the label did not exist until March 2025. That is a launch, not the defense of an established position, and the benchmark is built to test the second. What the five-year record does show is a franchise that grew from $0.84 billion of revenue in fiscal 2021 to $3.71 billion in fiscal 2025, mostly through better diagnosis and new labels. Tafamidis grew over the same span, which is what an expanding market looks like whether or not anyone is taking share. A position that has never been tested by a rival's counter-launch or a payer exclusion is not the same as a defended one.
Profitability: a real inflection with no decade behind it
Profitability: Moderate. Return on equity is not usable for this company. Book equity was negative at the end of fiscal 2022 and fiscal 2023 and stayed under $1 billion through fiscal 2025, which is why reported ROE reads negative 526% in fiscal 2022 and positive 362% in fiscal 2024. Those numbers describe the denominator. A ten-year ROIC would mislead for a related reason: accumulated deficits depress invested capital, and the asset base is mostly cash, so the ratio would measure the balance sheet's history rather than the productivity of the business. I use the income statement and cash flow directly instead.
| Fiscal year | Revenue (USD bn) | Operating income (USD bn) | Net income (USD bn) | Gross margin (%) | Operating cash flow (USD bn) |
|---|---|---|---|---|---|
| 2021 | 0.84 | -0.71 | -0.85 | 83.4 | -0.64 |
| 2022 | 1.04 | -0.78 | -1.13 | 83.7 | -0.54 |
| 2023 | 1.83 | -0.28 | -0.44 | 83.0 | 0.10 |
| 2024 | 2.25 | -0.18 | -0.28 | 85.6 | -0.01 |
| 2025 | 3.71 | 0.50 | 0.31 | 81.9 | 0.52 |
The gross margin has sat in an 81% to 86% band for five years, which says more about branded drug economics than about Alnylam: manufacturing is a small fraction of the price, so a successful rare-disease drug looks roughly like this. What moved is everything below the gross line. Operating income swung from a $0.71 billion loss in fiscal 2021 to $0.50 billion of income in fiscal 2025, and operating cash flow from negative $0.64 billion to positive $0.52 billion. The first half of fiscal 2026 continued the shift, with $0.50 billion of operating income on $2.46 billion of revenue, about a 20% operating margin.
Comparing profitability with the other two ATTR-CM sellers is harder than it looks. Tafamidis sits inside a diversified pharmaceutical company whose consolidated margin reflects hundreds of products, and BridgeBio's Attruby disclosure does not support a clean side-by-side. Directionally, both rivals have longer commercial records in this class, and Alnylam carried the franchise at an operating loss until fiscal 2025. Relative scale in a defined market against a fixed cost base is not something the company has yet earned.
What would move the rating
Two things would push the assessment toward Fairly Strong, and both are checkable. First, operating margin holding near or above 20% for several consecutive years, with free cash flow staying positive, would show the franchise earns above its cost of capital across a full cycle instead of in one good year. Second, Amvuttra holding its position in new ATTR-CM starts through a rival's counter-launch or a payer's formulary decision would show the entry barrier protects an incumbent's economics, not just the incumbent's ability to launch. Neither has happened yet. The rating would fall toward Weak if the ATTR-CM label failed to convert into durable pricing power, since that is where nearly all of the economics now sit.
Where the advantage comes from and how long it can last: delivery chemistry and a dual label
Two sources carry most of the weight. One is the galNAc delivery system and the siRNA design rules that sit on top of it, which let Alnylam turn a gene-silencing idea into a quarterly subcutaneous injection. The other is a label that is broader than either rival's, which lets one molecule serve two specialist audiences. Neither is customer captivity of the kind that keeps a prescriber from leaving when a better option appears, and the single strongest structural protection in this market, the approval hurdle, is one Alnylam shares with its competitors.
Supply-side advantage: delivery chemistry and design rules (Moderate)
The hard part of an RNAi drug is not the sequence. It is getting a fragile nucleic acid into the right cell type and keeping it active long enough to matter. Alnylam's answer is a sugar conjugate, galNAc, that binds a receptor abundant on liver cells, where transthyretin is made. Three consequences follow, in order.
First, the drug concentrates where the target protein is produced, so the dose can be small. Second, a small dose can be given subcutaneously instead of by intravenous infusion, which changes who can administer it and where. Onpattro, the earlier Alnylam product, is lipid-nanoparticle formulated and infused every three weeks; Amvuttra is conjugated and injected quarterly. That gap explains why Amvuttra displaced Onpattro commercially, and it is why the same chemistry now carries Amvuttra, Givlaari and Oxlumo. Third, reusing one delivery system across programs spreads the fixed cost of developing it and shortens the path to the next approval, because the pharmacokinetics and the safety database are largely known before the new sequence enters the clinic.
Ratings for supply-side edges should be given sparingly, and this one does not deserve better than Moderate. Conjugate chemistry is published science. Ionis and AstraZeneca built eplontersen on a comparable principle, and other companies have their own liver-targeting conjugates in trials, so the know-how does not by itself shut anyone out. What Alnylam has accumulated is process experience, a large clinical safety record and a manufacturing base built around its own molecules. Those shorten its next program and reduce the chance of a late failure. They do not stop a rival from entering, and the legal exclusion rests on patents with finite lives, which the company negotiates around rather than controls.
Demand-side advantage: quarterly dosing, thin switching costs (Moderate)
The switching cost for a prescriber here is close to the cost of writing a different prescription. No software is replaced, no workflow rebuilt, no staff retrained. Patients on a stable regimen have some inertia, and a quarterly injection that fits an ordinary clinic visit is easier to stay on than a daily pill regimen, but convenience is a product feature, not lock-in. If a rival showed better outcomes on mortality or hospitalization, or if a payer moved the class to a preferred product, the change would be a prescription edit.
Instruments to make clean, once: there are no network effects in a prescribed drug, where one more patient on therapy adds nothing to the value another patient receives.
What does create some stickiness is clinical routine. A cardiologist who has managed a patient on a quarterly injection for a year, with stable cardiac markers, has little reason to disturb it, and the patient has less. That shows up in retention, not in price. The test for pricing power is whether Alnylam can hold price while a rival discounts, and the recent record is not encouraging on that point: management guided full-year revenue to the low end of its range and flagged ordering volatility around the January 2027 340B pricing change. Channel and discount exposure moving the revenue line is what a franchise with negotiated pricing looks like. Demand-side rating: Moderate, and it leans on dosing convenience and routine, not on captivity.
Economies of scale: shared platform, limited production edge (Weak)
Fixed costs in this business are research, development and the commercial organization, and the fixed-cost base is genuinely reused: one delivery chemistry, one regulatory playbook, one payer-negotiating function across the portfolio. That is a real efficiency and it explains how the company reached operating profitability on $3.71 billion of revenue.
It does not build a barrier. Oligonucleotide synthesis is available from contract manufacturers, so a new entrant can buy capacity instead of building it, and the cost of goods is small relative to the price of the drug. Relative share matters little when the input cost is not the competitive variable. Distribution and brand spending here are aimed at a few thousand specialists, not at a national consumer audience, so there is no front-loaded network to amortize. Scale helps Alnylam run its own pipeline more cheaply than a startup could. It does not raise the cost of entry for anyone else, and without customer captivity behind it, scale in this market converts into margin only as long as pricing holds.
Durability: the substitute that ends the refill
The sharpest threat is a one-time therapy. At least one gene-editing candidate is in late-stage testing for ATTR-CM and works by shutting down TTR production permanently. If it succeeds, the underlying need is met in a single treatment and the quarterly injection becomes unnecessary for the patients who receive it. That attacks the recurring-revenue model directly, and no amount of delivery chemistry answers it. So far the evidence only shows that the approach is in testing; I have no outcome data and no approval, and one-time therapies have their own manufacturing, safety and reimbursement obstacles.
The milder substitute is the one already on the market. Stabilizers are oral, taken daily, supported by longer outcomes data, and cheaper for a health system to administer. If payers decide the oral option is good enough for a slice of patients, silencers lose pricing power at the margin without losing the market. Alnylam can also grow while losing share, since the treated population is bounded by how many patients get diagnosed at all; the same expanding diagnosis that lifts the whole class dilutes any single product's share.
Two observations would settle the durability question, and neither is available yet. One is a completed readout from the gene-editing program in ATTR-CM, because a permanent one-time therapy would reset the class's economics. The other is the trajectory of Alnylam's operating margin over the next three to four years. If it holds near 20% while rivals are also growing, the barrier to entry is protecting profit, and the moat is wider than Moderate implies. If margin compresses as the class fills up, the delivery chemistry was a head start that competition eventually priced away.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Alnylam Pharmaceuticals Inc compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Business, moat and key questions
Open company page